WSAAI 2023 60th Annual Scientific Session

February 5, 2023 to February 9, 2023

The Western Society of Allergy Asthma & Immunology consistently delivers high-quality, scientific lectures in the field of Allergy & Clinical Immunology in a unique format promoting attendee interaction with some of the foremost researchers and clinicians in our specialty.  Such conferences have been our notable achievement for over five decades. Among the subjects covered in the upcoming program are the effects of climate change and the urban environment on the incidence and manifestations of asthma and other allergic diseases, immunologic aspects of SARS-CoV-2 disease in immunocompetent and immunodeficient patients, the pathologic role of effector cells including mast cells and eosinophils in the expression of disease states, the evaluation, diagnosis and treatment of chronic disorders characterized by cough, pruritus or anaphylaxis and current and emerging treatments of venom allergy, eosinophilic esophagitis, and food allergy.

Accreditation   
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Western Society of Allergy, Asthma & Immunology (WSAAI).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 21.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 21 contact hours. 

Target Audience

Allergists and Allied Health Providers

Learning Objectives

At the end of this activity, learners should be able to...

•    Recognize changes in pollen patterns that can impact allergy and respiratory disease.
•    Recognize the association between climate and allergen sensitization.
•    Provide education and guidance on impact of climate and weather on mold contamination.
•    Recognize factors that correlate with the severity of anaphylaxis.
•    Implement guidance on ordering tryptase levels in patients with Hymenoptera anaphylaxis.
•    Incorporate recombinant venom allergens in venom immunotherapy decision making.
•    Define asthma classification by endotype and phenotype
•    Describe biomarkers associated with asthma endotypes and phenotypes
•    Apply knowledge of endotypes and phenotypes to guide selection of asthma therapeutics 
•    Perform differential diagnosis of eosinophilic disorders
•    Identify patients with HES
•    Discuss management of patients with eosinophilic disorders
•    Discuss immediate treatment of anaphylaxis during the ongoing COVID-19 Pandemic
•    Understand the unique nature of RNA-virus driven respiratory disease & its global impact
•    Understand the immune response to SARS-CoV-2 infection in immunocompetent & immunodeficient patients
•    Order, evaluate and interpret appropriate laboratory tests for the diagnosis of primary immunodeficiency
•    Differentiate MCAS from systemic mastocytosis & understand management of each condition
•    Understand histaminergic and non-histaminergic mechanisms of pruritus
•    Effectively manage patients with chronic poorly-controlled pruritus
•    Discuss the differential diagnosis of chronic cough
•    Treat chronic cough effectively based upon an understanding of origin, pathophysiology & available therapies
•    Discuss current and emerging therapies for patients with food allergy, eosinophilic esophagitis & eczema

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 21.00 AMA PRA Category 1 Credit™
  • 21.00 Attendance
  • 21.00 CBRN
Course opens: 
02/05/2023
Course expires: 
12/31/2025
Event starts: 
02/05/2023 - 3:00pm CST
Event ends: 
02/09/2023 - 4:20pm CST
Add to calendar: 
Rating: 
0

Western Society of Allergy, Asthma & Immunology
60th Annual Scientific Session
February 5-9, 2023

SUNDAY, FEBRUARY 5, 2023

3:00-5:00 PM         REGISTRATION, POSTER SESSION, EXHIBITS 
6:00-8:00 PM         WELCOME RECEPTION

MONDAY, FEBRUARY 6, 2023

6:45 AM         WELCOME AND INTRODUCTION, René Anderson-Cowell, MD, Program Director/President Elect 
SESSION MODERATOR: Steve Machtinger, MD, President

7:00 AM        The Donald Stevenson, MD Lecture, Global Impact of Climate Change - Sayantani B. Sindher, MD
7:50 AM        Q&A

8:00 AM        Immunobiology of Coronavirus and Emergence of New Viral Variants - Florian Krammer, PhD
8:50 AM        Q&A

9:00 AM        Interaction Between Climate & Allergic Diseases - Jeffrey G Demain, MD, FAAP, FACAAI, FAAAAI
9:50 AM        Q&A

10:00AM         BREAK/EXHIBITS/POSTERS

10:30AM        Asthma – Inner City - Fernando D. Martinez, MD 
11:20 AM        Q&A

11:30 AM        Asthma Phenotypes and Endotypes - Princess Ogbogu, MD 
12:20 PM        Q&A

12:30 PM    Adjourn

TUESDAY, FEBRUARY 7, 2023

11:30 AM         EXHIBITS/POSTERS

12:15 PM        SESSION MODERATOR
David Elkayam, MD. Secretary/Treasurer

12:30 PM        The Harold S. Nelson, MD Lecture, Primary Immunodeficiency - Jordan S. Orange, MD, PhD 
1:20 PM            Q&A

1:30 PM    Vaccine Development Now and into the Future-What Did Coronavirus Teach Us? - Florian Krammer, PhD
2:20 PM    Q&A

2:30 PM         BREAK/EXHIBITS/POSTERS

3:00 PM    Oral Immunotherapy with Biologics: Emerging Medical Therapies for Food Allergy - Sayantani Sindher, MD
3:50 PM    Q&A


4:00 PM    Evolving Diagnostics Work-Up and Approach to Treating Immune Deficiency - Jordan S. Orange, MD, PhD
4:50 PM    Q&A

5:00 PM            Adjourn

WEDNESDAY, FEBRUARY 8, 2023

7:00 AM         WSAAI MEMBER BREAKFAST/BUSINESS MEETING 

7:00 AM         EXHIBITS/BREAK/POSTERS

8:15 AM        SESSION MODERATOR: Matthew Bowdish, MD Immediate Past President

8:30 AM        Pediatric Eosinophilic Esophagitis Update - Carla Davis, MD
9:20 AM        Q&A    

9:30 AM        Persistent Cough in Childhood - Fernando D. Martinez, MD
10:20 AM        Q&A

10:30 AM        Eczema Prevention, Diagnosis and Itch Management - Eric L. Simpson, MD, MCR
11:20 AM        Q&A

11:30 AM         BREAK/EXHIBITS/POSTERS

12:00 PM        Mast-Cell Activation/Non-IgE Mediated Mechanisms of Drug Induced Mast Cell Deregulation - Melody Carter, MD
12:50 PM        Q&A

1:00 PM            Venom Hypersensitivity Update - Jeffrey G Demain, MD, FAAP, FACAAI, FAAAAI
1:50 PM            Q&A

2:00 PM            Adjourn

THURSDAY, FEBRUARY 9, 2023

11:00 AM         EXHIBITS/POSTERS

11:45 PM        SESSION MODERATOR
René Anderson-Cowell, MD Program Director/President Elect

12:00 PM        Food Allergy Update – What’s New - Carla Davis, MD
12:50 PM        Q&A

1:00 PM         Atopic Dermatitis Treatment Update - Eric Simpson, MD, MCR
1:50 PM            Q&A

2:00 PM            BREAK/EXHIBITS/POSTERS

2:30 PM            Anaphylaxis Update - Melody Carter, MD
3:20 PM            Q&A

3:30 PM            Eosinophilia: Advances and Insights in Diagnosis and Management - Princess Ogbogu, MD
4:20 PM            Q&A

4:30 PM            Adjourn

6:00 PM-8:00PM        FAREWELL RECEPTION

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All relevant financial relationships with ineligible companies have been mitigated.

The individuals listed below disclose the following financial relationships:

Carla M. Davis, MD, Speaker
Researcher: Allergenis, Regeneron
Speaker: Takeda

Jeffrey G Demain, MD, Speaker
Speaker: Merck
Advisor: AstraZeneca
Consultant: Merck

Florian Krammer, PhD, Speaker
Independent contractor: Pfizer
Consultant: Pfizer, GSK, Avimex

Princess Ogbogu, MD, Speaker
Advisor: AstraZeneca, GSK, Sanofi
Researcher: AstraZeneca, GSK

Jordan S. Orange, MD, PhD, Speaker
Consultant: Grifols, CSL Behring, Editas, Takeda, Teva
Advisor: ADMA

Eric L. Simpson, MD, MCR, Speaker
Researcher: AbbVie, Amgen, Arcutis, Aslan Pharma, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Kyowa Kirin, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme
Consultant: AbbVie, Amgen, AOBiome LLC, Arena Pharmaceuticals, Aslan Pharma, Boehringer Ingelheim USA, Inc., Bristol Myers Squibb-BMS, CorEvitas, Dermira, Eli Lilly, Evelo Biosciences, Forte Bio RX, Galderma, GlaxoSmithKline, Incyte, Janssen, Johnson & Johnson, Kymab, Kyowa Kirin, Leo Pharma, Merck, Pfizer, Regeneron, Roivant, Sanofi-Genzyme, Valeant

Sayantani B. Sindher, MD, Speaker
Independent contractor: Aimmune Therapeutics, DBV Technologies
Researcher: Aimmune Therapeutics, DBV Technologies

David Elkayam, MD, Planner, Moderator
Researcher: AstraZeneca, Genentech, Novartis, Siva, Bellus Health, Allergy Therapeutics, Suzhou
Consultant: Siva

Matthew Bowdish, MD, Planner, Moderator
Speaker: GSK, AstraZeneca, Boehringer-Ingelheim
Advisor: AstraZeneca, Boehringer-Ingelheim

Andrew White, MD, Planner
Advisor: Regeneron/Sanofi, Amgen/AstraZeneca, ALK, BluePrint, Genentech, GSK
Speaker: Regeneron/Sanofi, AstraZeneca, Amgen/AstraZeneca, BluePrint, GSK
Researcher: Regeneron/Sanofi, AstraZeneca

Amy Wagelie-Steffen, MD, Planner
Advisor: AstraZeneca, Sanofi/Genzyme, Regeneron, Amgen, BioCryst, Pharming, Genentech
Speaker: AstraZeneca, Sanofi/Genzyme, Regeneron, Amgen, Genentech

Marc Riedl, MD, Planner
Consultant: Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, KalVista, Pfizer, Pharming, Pharvaris, Sanofi-Regeneron, Takeda
Researcher: Biocryst, Biomarin, CSL Behring, KalVista, Pharvaris, Takeda
Speaker: CSL Behring, Grifols, Pharming, Takeda

The following have no relevant financial relationships with ineligible companies to disclose:

Melody Carter, MD, Speaker
Fernando D. Martinez, MD, Speaker
René Anderson-Cowell, MD, Planner, Moderator
Steve Machtinger, MD, Planner, Moderator
Jinny Chang, MD, Planner
Karol Anderson, Planner

Available Credit

  • 21.00 AMA PRA Category 1 Credit™
  • 21.00 Attendance
  • 21.00 CBRN
Please login or create an account to take this course.